Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 379

1.

Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up.

Langston ME, Pakpahan R, Nevin RL, De Marzo AM, Elliott DJ, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S.

Prostate. 2018 Sep;78(13):1024-1034. doi: 10.1002/pros.23660. Epub 2018 May 30.

PMID:
30133756
2.

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB.

Prostate. 2018 Jul 24. doi: 10.1002/pros.23697. [Epub ahead of print]

PMID:
30043417
3.

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T.

Br J Cancer. 2018 Jul 10. doi: 10.1038/s41416-018-0172-0. [Epub ahead of print]

PMID:
29988112
4.

Calcium signaling: an underlying link between cardiac disease and carcinogenesis.

Xu X, Balk SP, Isaacs WB, Ma J.

Cell Biosci. 2018 Jun 8;8:39. doi: 10.1186/s13578-018-0236-0. eCollection 2018. No abstract available.

5.

Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

Helfand BT, Chen H, Fantus RJ, Conran CA, Brendler CB, Zheng SL, Walsh PC, Isaacs WB, Xu J.

Prostate. 2018 Jun 19. doi: 10.1002/pros.23664. [Epub ahead of print]

PMID:
29923209
6.

Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis.

Na R, Wu Y, Jiang G, Yu H, Lin X, Wang M, Conran CA, Fantus RJ, Zhang N, Liu S, Helfand BT, Zheng SL, Isaacs WB, Ding Q, Shen Z, Xu J.

BJU Int. 2018 May 4. doi: 10.1111/bju.14370. [Epub ahead of print]

PMID:
29727914
7.

Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and Drosophila melanogaster.

Ghartey-Kwansah G, Li Z, Feng R, Wang L, Zhou X, Chen FZ, Xu MM, Jones O, Mu Y, Chen S, Bryant J, Isaacs WB, Ma J, Xu X.

BMC Dev Biol. 2018 Mar 27;18(1):7. doi: 10.1186/s12861-018-0167-3. Review.

8.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J.

Prostate. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9.

PMID:
29520813
9.

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.

Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.

PMID:
29439820
10.

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.

Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.

PMID:
29368341
11.

The expression of AURKA is androgen regulated in castration-resistant prostate cancer.

Kivinummi K, Urbanucci A, Leinonen K, Tammela TLJ, Annala M, Isaacs WB, Bova GS, Nykter M, Visakorpi T.

Sci Rep. 2017 Dec 21;7(1):17978. doi: 10.1038/s41598-017-18210-3.

12.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

13.

Genetic factors influencing prostate cancer risk in Norwegian men.

Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, Djurovic S, Andreassen OA, Axcrona K, Mills IG, Xu J, Maehle L, Fosså SD, Isaacs WB.

Prostate. 2018 Feb;78(3):186-192. doi: 10.1002/pros.23453. Epub 2017 Nov 27.

PMID:
29181843
14.

Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.

Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Stern MC, Jarai ZK, Govindasami K, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann T, Drake BF, Hu JJ, Clark PE, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJM, Han Y, Lubwama A, Thompson IM Jr, Leach R, Easton DF, Schumacher F, Van den Berg DJ, Gundell SM, Stram A, Wan P, Xia L, Pooler LC, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten J, Kibel AS, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Klein EA, Brureau L, Stram DO, Watya S, Chanock SJ, Witte JS, Blot WJ, Henderson BE, Haiman CA; PRACTICAL/ELLIPSE Consortium.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx084.

15.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

PMID:
28790115
16.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

17.

Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection.

Milbrandt M, Winter AC, Nevin RL, Pakpahan R, Bradwin G, De Marzo AM, Elliott DJ, Gaydos CA, Isaacs WB, Nelson WG, Rifai N, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S.

Prostate. 2017 May;77(13):1325-1334. doi: 10.1002/pros.23392. Epub 2017 Jul 12.

18.

A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J.

Prostate. 2017 Aug;77(11):1213-1220. doi: 10.1002/pros.23380. Epub 2017 Jun 28.

19.

Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto GJ, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL.

Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26.

20.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

Supplemental Content

Loading ...
Support Center